Emstopa
Develops an antibody-based drug to reverse tPA-induced bleeding for patients with cardiac surgery complications and major trauma
Highlights
- New on EvolcAdded 2026-11-14
About Emstopa
EmstoPA is a preclinical biopharmaceutical company developing a humanised antibody fragment that targets tissue plasminogen activator (tPA) to reduce tPA-induced bleeding. The programme focuses on haemorrhage associated with cardiac surgery, major trauma and thrombolysis.
The company is seeking capital investment or partnerships to advance the programme to clinical development. It has received scientific advice from the FDA and MHRA and is recommended for the UK ILAP Accelerated Access Programme.
EMSTOPA LIMITED was founded in 2017 and is headquartered in Sandwich, United Kingdom. Its intellectual property is licensed exclusively from the University of Tennessee, with exclusivity through 2039.
Product: A humanised antibody fragment in preclinical development to block tPA activity and reduce tPA-induced haemorrhage.
Jobs at Emstopa
Leadership
- James C Keith Jr · Chief Executive OfficerSource: company website
More biotech & pharma companies
Enara Bio
Cancer immunotherapies for patients with solid tumors, developed using dark-antigen discovery and T-cell engager platformsEngivent
Programmable microfluidic and automation systems for biology and biotechnology research teamsYoung companyNew on EvolcEnhanced Genomics
Genomics platform and drug discovery programs for pharmaceutical partners developing therapies for human diseasesNew on EvolcEnsilicated Technologies
Silica-based biomolecule stabilization technology for biopharmaceutical developers seeking to reduce cold-chain dependenceNew on EvolcEnsocell
AI-driven discovery of precision therapies for fibrotic and autoimmune diseases using human biological dataYoung companyEnterobiotix
Clinical-stage microbiome therapeutics developer advancing oral EBX-102-02 for irritable bowel syndrome and seeking licensing partners
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Analytics
- Google Analytics 4High confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- nginxHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.